23-MYEL-20-CB-PMC: A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

Grants and Contracts Details

StatusActive
Effective start/end date1/17/241/17/26

Funding

  • Caribou Biosciences Incorporated: $18,605.00